UFP Technologies Posts $172.4 Million Q3 Sales
The medical device maker reported 11.6% year-over-year sales growth while shifting labor-intensive production to the Dominican Republic.
Updated on Nov. 5, 2026 in Manufacturing
UFP Technologies reported third-quarter 2026 sales of $172.4 million, up 11.6% year-over-year, with organic growth of 11.1%. The company is also moving labor-intensive AJR medical product assembly to the Dominican Republic.
Why it matters
The production shift is intended to reduce expenses, while the company keeps funding internal growth and expanding its credit facility to pursue larger acquisitions. Customer qualification requirements have pushed back the timeline for the transfer.
UFP Technologies reported $172.4 million in third-quarter 2026 sales, up 11.6% year-over-year, with organic growth of 11.1% and medical technology sales up 12.5%. The company's leverage ratio ended the quarter well under 1x, but the timing of the Dominican Republic transfer remains unsettled pending customer qualification.
The details
Management is moving AJR's labor-intensive medical product assembly to the Dominican Republic, with new capacity expected online in 2027. The company is funding internal growth while expanding its credit facility to pursue larger target companies.
Timeline
Q3 2026: UFP Technologies reports $172.4 million in quarterly sales.
November 4, 2026: The company holds its third-quarter earnings call.
2027: New Dominican Republic manufacturing capacity expected to come online.
Market Landscape
The Dominican Republic shift follows a broader pattern of medical device manufacturers relocating labor-intensive assembly to lower-cost production sites in the Caribbean and Latin America. UFP is pairing that move with a credit-facility expansion aimed at acquiring larger companies in the same sector.
For consumers and hospital buyers of AJR medical products, the production move could affect cost structures over time, though the timeline depends on customer qualification. The transfer's pace remains unsettled, so near-term product sourcing is not expected to change.
The takeaway
Rising sales alongside a shift in manufacturing footprint suggests UFP is pursuing growth and cost reduction at the same time. Investors and industry watchers will track whether the 2027 capacity ramp in the Dominican Republic meets its timeline.
Further reading
For broader context on production relocation, see Manufacturing.
Source note: This article includes information reported by The Motley Fool.
